The COPERNICUS study of amivantamab/lazertinib showed lower rates of adverse events and discontinuation with supportive care regimens in patients with EGFR-mutated non–small cell lung cancer.
|Videos|May 18, 2018
Treatment Considerations for Unresectable Locally Advanced NSCLC
Treatment Considerations for Unresectable Locally Advanced NSCLC
Advertisement
- A 64-year-old man presented with shortness of breath and persistent cough of 18 months’ duration; recently, he has experienced chest pain, fatigue, and blood in his sputum. After consulting with his primary care physician, he was referred for oncology evaluation
- Patient history includes
- Current smoker (1/2 pack day)
- Hypertension
- Acute MI at age 60
- Evaluation and follow up testing reveal
- Non-small cell lung cancer in left lung and 2 lymph nodes (Stage IIIa)
- WHO performance status: 1
- Histology: adenocarcinoma
- EFGR, BRAF,andALK/ROS1mutation status: wild-type
- PD-L1 status: ≥25%
- He underwent multidisciplinary evaluation and was not a candidate for surgery; he was treated with chemoradiotherapy:
- Concurrent carboplatin-paclitaxel doublet chemotherapy and radiotherapy (60 Gy)
- Achieved partial response
- He had no disease progression 20 days after his last radiotherapy treatment, and began treatment with durvalumab
Advertisement
Related to this article
Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
The FDA approved an sNDA updating the taletrectinib label with a 49.7-month median duration of response from TRUST-I in ROS1-positive NSCLC.
US cancer deaths keep falling as lung cancer declines; smoking drops, screening rises, but rural and low-education gaps persist.
David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
SOT106 Receives New FDA FTD and ODD in Sarcoma
2
IMS 2026 Day 4 Recap: MRD-Guided Regimens Highlight Final Sessions
3
Iberdomide Doubles MRD-Negative CR Rate in Phase 3 EXCALIBER-RRMM Trial
4
IMS 2026 Day 3 Recap: Etentamig Outperforms Standard Therapy in RRMM Trial
5